Holen Sie sich die Stockscreener-App
6.18
9.19%
0.52
Vorhandelsmarkt:
5.24
-0.94
-15.21%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline - TipRanks
Altimmune (ALT) Prepares for Phase 3 Trial with New Funding - GuruFocus
Altimmune prices $75M direct offering - MSN
Altimmune Secures $75M from Institutional Investor in Direct Offering - Intellectia AI
Altimmune (ALT) Secures $75M in Direct Offering to Fund Phase 3 Trial - GuruFocus
ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon - Stocktwits
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock - The Manila Times
Trend Recap: Will Altimmune Inc stock hit new highs in YEAR - baoquankhu1.vn
Altimmune raises $75 million to fund MASH therapy development - Investing.com
Altimmune raises $75 million to fund MASH therapy development By Investing.com - Investing.com UK
Biotech Altimmune raises $75M to prepare Phase 3 MASH liver trial - Stock Titan
Evercore ISI lowers Altimmune stock price target to $22 from $25 - Investing.com Canada
Revenue Check: Is Altimmune Inc a speculative investmentDollar Strength & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Why Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag For Obesity-MASH DrugAnd What's Next - Yahoo Finance
Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly - Yahoo Finance
Altimmune (NASDAQ:ALT) Trading 16.1% HigherShould You Buy? - MarketBeat
Altimmune Stock Surges After FDA Breakthrough for MASH Therapy - StocksToTrade
Stock Traders Purchase High Volume of Call Options on Altimmune (NASDAQ:ALT) - MarketBeat
Booz Allen Posts Upbeat Q3 Earnings, Joins Life360, Redwire And Other Big Stocks Moving Higher On Friday - Benzinga
ALT stock rallies 4% — what does retail think? - MSN
Altimmune (ALT) Receives FDA Breakthrough Therapy Designation, Shares Rise Nearly 4% - Intellectia AI
Decliners Report: Can Altimmune Inc stock outperform in a bear marketJuly 2025 PostEarnings & Expert-Curated Trade Recommendations - baoquankhu1.vn
Rate Hike: Is Altimmune Inc stock a value trapJuly 2025 News Drivers & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Bitcoin Whales Accumulate While Retail Investors Withdraw - Intellectia AI
Altimmune receives FDA’s breakthrough therapy designation for its liver disease drug - MSN
Is Altimmune Inc a strong candidate for buy and holdPortfolio Update Report & Risk Managed Investment Signals - baoquankhu1.vn
Market Pulse: Can Altimmune Inc keep up with sector leadersOptions Play & Growth Focused Stock Reports - baoquankhu1.vn
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
RSI Check: Can Stran Company Inc Equity Warrant beat the S P 500Portfolio Risk Report & Reliable Intraday Trade Plans - baoquankhu1.vn
Rally Mode: Is Altimmune Inc stock a good pick for beginners2025 Volume Leaders & Safe Entry Zone Tips - baoquankhu1.vn
Can Altimmune's Pemvidutide Follow In The Footsteps Of Rezdiffra And Wegovy In The MASH Landscape? - RTTNews
Dow Update: Will Altimmune Inc stock recover faster than peersJuly 2025 Chart Watch & Reliable Breakout Forecasts - moha.gov.vn
Will Altimmune Inc. stock benefit from upcoming earnings reports2025 Earnings Surprises & Advanced Technical Signal Analysis - Улправда
Enovix, Serve Robotics, EOG, Altimmune, Globalstar Shake Markets - TipRanks
Wayne Pisano Increases Stake in Altimmune Inc with Recent Share Purchase - GuruFocus
Wayne Pisano Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat
Altimmune (ALT) Is Up 13.0% After FDA Breakthrough Tag For Pemvidutide In MASHHas The Bull Case Changed? - Yahoo Finance
Can Altimmune Inc. stock sustain free cash flow growthJuly 2025 Volume & Momentum Based Trading Ideas - ulpravda.ru
Published on: 2026-01-09 03:53:26 - ulpravda.ru
Entry Recap: Will Altimmune Inc. stock split attract more investors2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - Улправда
Will Altimmune Inc. stock split attract more investorsPortfolio Return Summary & Fast Moving Market Watchlists - ulpravda.ru
Swing Trade: Why Altimmune Inc. stock remains on buy listsJuly 2025 Selloffs & Smart Allocation Stock Reports - ulpravda.ru
Altimmune (ALT) Is Up 16.1% After FDA Breakthrough Nod For AI-Enhanced MASH Drug Trial – Has The Bull Case Changed? - simplywall.st
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH - The Globe and Mail
Altimmune gains on FDA breakthrough designation for MASH therapy - MSN
Altimmune’s Surprising Stock Surge: What’s Behind It? - StocksToTrade
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Altimmune shares rally after FDA awards breakthrough status to pemvidutide - MSN
Why Did Mobileye Stock Surge 8% Pre-Market Today? - Stocktwits
Altimmune (ALT) Surges on FDA Breakthrough Therapy Designation f - GuruFocus
Altimmune Receives FDA Breakthrough Therapy Designation For Pemvidutide In Mash - TradingView — Track All Markets
Altimmune stock gains on FDA breakthrough status (ALT:NASDAQ) - Seeking Alpha
FDA grants breakthrough therapy status to Altimmune’s MASH drug By Investing.com - Investing.com Australia
Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug - TradingView — Track All Markets
Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Quiver Quantitative
Altimmune stock soars after FDA grants Breakthrough Therapy status By Investing.com - Investing.com Canada
Altimmune stock soars after FDA grants Breakthrough Therapy status - Investing.com
FDA grants breakthrough therapy status to Altimmune’s MASH drug - Investing.com
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):